Form 4: Thermo Fisher Scientific CEO Marc Casper Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Thermo Fisher Scientific's CEO, Marc Casper, reports acquisition of performance-based restricted stock units and updates to his beneficial ownership.
Summary
- Marc N. Casper, CEO of Thermo Fisher Scientific, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
- The report includes the acquisition of 70,769 performance-based restricted stock units on May 21, 2025, which will vest on May 21, 2030, subject to certain conditions.
- Casper directly owns 115,173.623 shares of common stock.
- He also indirectly owns shares through the Alison Casper 2020 Irrevocable Trust (11,300 shares), Floral Park Associates, Inc. (14,608 shares), and the MNC 2020 Irrevocable Trust (5,000 shares).
- Casper disclaims beneficial ownership of the indirectly owned securities, except to the extent of any pecuniary interest.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The filing reflects standard executive compensation practices and aligns management incentives with shareholder value through performance-based equity.
Positives
- The acquisition of performance-based restricted stock units aligns the CEO's interests with the long-term performance of the company.
- The vesting criteria based on TSR relative to the S&P 500 Equal Weight Index incentivizes outperformance.
Future Outlook
The performance-based restricted stock units will vest in 2030 based on the company's performance relative to the S&P 500 Equal Weight Index.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The grant of performance-based restricted stock units aligns the CEO's interests with those of shareholders, incentivizing long-term value creation.
Key Dates
| Date | Description |
|---|---|
| 05/01/2025 | Start date of the performance period for the performance-based restricted stock units. |
| 05/21/2025 | Date of transaction: Grant of performance-based restricted stock units. |
| 05/22/2025 | Date of filing the Form 4. |
| 12/31/2029 | End date of the performance period for the performance-based restricted stock units. |
| 05/21/2030 | Vesting date for the performance-based restricted stock units. |
Keywords
Thermo Fisher Scientific, Marc Casper, beneficial ownership, Form 4, restricted stock units, TSR, S&P 500
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.